Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.52 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8481945 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7491950 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27970690 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7491943 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7823845 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8481947 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8482485 | 1.00 | CHRNB2 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7424981 | 0.88 | CYP2D6 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7424991 | 0.88 | CYP2D6 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7424985 | 0.88 | CYP2D6 (0.64) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490994-B1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-109661398-B | Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. | 2022-03-31 | — | — | US | disclosed |
| US-11192875-B2 | Processes for preparing antiviral compounds | GILEAD PHARMASSET LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2018-06-28 | — | — | US | disclosed |
| WO-2018026792-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2907816-A1 | Condensed imidazolylimidazoles as antiviral compounds | Gilead Pharmasset LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014100500-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| EP-0874849-B1 | 2,7-SUBSTITUTED OCTAHYDRO-PYRROLO 1,2-A]PYRAZINE DERIVATIVES | PFIZER (US) | 2001-09-19 | — | — | EP | disclosed |
| US-6284757-B1 | ANTISEROTINONE AGENT | PFIZER INC. | 2001-09-04 | — | — | US | disclosed |
| EP-0982030-A2 | 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands | Pfizer Products Inc. (US) | 2000-03-01 | — | — | EP | disclosed |
| US-5942537-A | ADMINISTERING A L-TRANS PYRROLIDINE DERIVATIVE TO INHIBIT THE TRANSPORT OF L-GLUTAMATE OR L-ASPARTATE OR AN EXCITATORY AMINO ACID NEUROTRANSMITTER AWAY FROM A SYNAPSE COMPRISING CONTACTING SYNAPSE WITH PYRROLIDINE DERIVATIVE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-08-24 | — | — | US | disclosed |
| US-5714487-A | 2,7-substituted octahydro-pyrrolo 1,2-a!pyrazine derivatives | PFIZER INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0497895-A1 | METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991006536-A1 | METHOD OF INHIBITING THE TRANSPORT OF L-GLUTAMATE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192875-B2 | Processes for preparing antiviral compounds | MAVS, EIF2AK2, SAMHD1 | CHRNB2 4876/4885CHRNA4 4857/4885CHRNB4 4852/4885 |
| US-20180179175-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | CHRNB2 4876/4885CHRNA4 4857/4885CHRNB4 4852/4885 |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | CHRNB2 1110/4885CHRNA4 279/4885CHRNB4 936/4885 |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | CHRNB2 1110/4885CHRNA4 279/4885CHRNB4 936/4885 |
| US-20200392100-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | CHRNB2 4876/4885CHRNA4 4857/4885CHRNB4 4852/4885 |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | CHRNB2 1110/4885CHRNA4 279/4885CHRNB4 936/4885 |
| US-20190263771-A1 | PROCESSES FOR PREPARING ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SAMHD1 | CHRNB2 4876/4885CHRNA4 4857/4885CHRNB4 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.